Investors
and Media
News Releases
-
Dec 9, 2019- Interim Phase 2a Data Demonstrate Improved Overall Response Rate in Combination with Rituximab -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
Dec 8, 2019- Interim Results Demonstrate Good Tolerability and Clinical Response in Patients with Relapsed/Refractory PTCL and CTCL -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
Nov 15, 2019- Recommendations from Multidisciplinary Expert Panel on Anticoagulant Reversal and Replacement Guidance Published in Annals of Emergency Medicine -
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary...
-
Nov 6, 2019- Cerdulatinib Interim Phase 2a Data Highlight Efficacy and Safety Results in Patients with Heavily Pre-Treated T-Cell Malignancies and Follicular Lymphoma -
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, will...
-
Nov 5, 2019- Andexxa®/Ondexxya® Net Product Revenues of $35.7 million, a 32% Increase Over the Prior Quarter -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended September 30, 2019, and provided a corporate update. "We delivered another quarter of...
-
Nov 1, 2019
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) announced today that on October 31, 2019, the Compensation Committee of the Board of Directors approved, effective as of October 31, 2019, the grant...
-
Oct 28, 2019- Effective Hemostasis Achieved in 82% of Evaluable Patients with Acute Gastrointestinal Bleeding -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new exploratory analysis of data from ANNEXA-4, the Company's Phase 3b/4 trial of its Factor Xa inhibitor...
-
Oct 15, 2019
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended September 30, 2019,...
-
Sep 19, 2019
Portola Pharmaceuticals, Inc. (Nasdaq: PTLA) today announced the appointment of Ted W. Love, M.D., to its Board of Directors. Dr. Love is a recognized industry leader with more than 25 years of...
-
Aug 22, 2019
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...
-
Aug 13, 2019
Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In...
-
Aug 12, 2019
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The...
-
Aug 7, 2019- Second Quarter Revenues of $28.4 Million; Andexxa® Net Product Revenues Grow to $27.1 Million -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended June 30, 2019, and provided a corporate update. "This is our fifth consecutive quarter of...
-
Aug 6, 2019- Expands Patient Access to the First and Only Factor Xa Reversal Agent Approved in Europe for Life-Threatening Bleeds Associated with the Use of Rivaroxaban or Apixaban -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the Company's first sales of Ondexxya® (andexanet alfa) in Europe. These sales mark the initiation of commercial access in Europe to...
-
Aug 5, 2019- Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has increased the maximum reimbursement amount for the New Technology...
-
Jul 17, 2019
Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company's financial results for the quarter ended June 30, 2019, and...
-
Jul 8, 2019- Data Presented at the Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH 2019) -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new invitro data establishing the relationship between concentrations of the direct oral anticoagulants (DOACs) apixaban and...
-
Jun 19, 2019- Interim Phase 2a Data Highlight Efficacy and Safety Results of Cerdulatinib Alone and in Combination with Rituximab -
Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced new interim results from the Company's ongoing Phase 2a study of cerdulatinib, an investigational, oral SYK/JAK inhibitor, in...
-
May 28, 2019
May 28, 2019 PDF Version SOUTH SAN FRANCISCO, Calif., May 28, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola’s president and...
-
May 22, 2019– Excellent or Good Hemostasis Achieved in 79% of Evaluable Patients with Spontaneous Intracranial Hemorrhage –
SOUTH SAN FRANCISCO, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced the presentation of a new analysis of data from an important subgroup...
-
May 8, 2019– First Quarter Revenues of $22.2 Million; Andexxa® Product Revenues Grow 45% to $20.3 Million –
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. ® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2019 and...
-
Apr 26, 2019– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding –
SOUTH SAN FRANCISCO, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing...
-
Apr 24, 2019
SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that John Curnutte, M.D., Ph.D., Executive Vice President and Head of...
-
Apr 17, 2019
SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company’
-
Mar 20, 2019
SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...